Healthcare Equipment and Supplies
Company Overview of Tryton Medical, Inc.
Tryton Medical, Inc. manufactures and sells stent systems for the treatment of bifurcation lesions. The company offers Side Branch Stent System, which is used to treat a range of bifurcated lesions. It sells its products through distributors in Austria, the Benelux countries, Czech Republic, Slovak Republic, Latvian Republic, Denmark, Germany, Hungary, Ireland, Israel, Italy, Jordan, Pakistan, Poland, Portugal, the Russian Federation, Saudi Arabia, Spain, Sweden, Switzerland, Turkey, the United Arab Emirates, and the United Kingdom. The company was founded in 2003 and is based in Durham, North Carolina.
1000 Park Forty Plaza
Durham, NC 27713
Founded in 2003
Key Executives for Tryton Medical, Inc.
Compensation as of Fiscal Year 2012.
Tryton Medical, Inc. Key Developments
Tryton Medical Announces CE Mark and European Launch of Next-Generation Tryton Side Branch SHORT Stent
May 16 13
Tryton Medical, Inc. announced that the company received the CE Mark for the Tryton Side Branch SHORT Stent, a novel coronary stent system that broadens the treatment options in bifurcations in large vessels with a short main branch landing zone. The Tryton Side Branch SHORT Stent length is 15 mm, or 3mm shorter in the main branch zone than the standard Tryton Side Branch Stent. The company is launching the product immediately in CE Mark countries. This innovation leverages the company's proprietary, first-in-class Tri-ZONE(R) technology and adds to the Tryton family of stents. The company will launch the Tryton Side Branch SHORT Stent during EuroPCR 2013 in Paris at their exhibitor booth #M27. The Tryton Side Branch SHORT Stent is supported by the robust clinical evidence of the Tryton Side Branch Stent. Published data from more than 1,000 patients treated with the Tryton Side Branch Stent in more than 8 European post-marketing registries demonstrated low target lesion revascularization rates of 2.9% at six months and 4.0% at one year, and a low 0.5% thrombosis rate at one year. More than 7,500 patients have been treated with the Tryton Side Branch Stent and it is commercially available throughout Europe, Russia and the Middle East. The Tryton Side Branch Stent is an investigational device in the United States. Tryton has completed enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent and anticipates study outcomes will be presented at TCT 2013 in San Francisco.
Tryton Medical, Inc. Presents Positive Data from More Than 900 Patients at TCT 2012 Conference in Miami
Oct 29 12
Tryton Medical, Inc. announced the latest data from a pooled analysis of 905 patients treated with the Tryton Side Branch Stent.(TM). In addition, the company announced live satellite transmissions of two successful clinical cases using the Tryton stent to audiences of over 1,000 interventional cardiologists attending the conference. Data from the analysis of eight registry studies showed that in the real-world setting, the rate of target lesion revascularization (TLR) for bifurcation lesions treated with the Tryton stent was 4% at one year, with a stent thrombosis rate of 0.5%. These results and other findings from various registries were confirmed in SAFE-Try, the large prospective multicenter trial to date of the Tryton stent, which evaluated safety and efficacy in 251 patients. Data, which were presented at TCT by Giuseppe Tarantini of the University of Padua in Padua, Italy, showed a TLR of 4.4% and zero stent thrombosis at nine months.
Tryton Medical, Inc. Announces Clinical Data from More Than 900 Patients Treated with its Bifurcation Stent System at EuroPCR 2012
May 23 12
Tryton Medical, Inc. announced results of a patient-level pooled analysis of six-month clinical outcomes of the TRYTON Side Branch Stent. Findings were presented in Paris at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions. Data from 905 patients treated with the Tryton stent in eight European post-marketing registries demonstrated low target lesion revascularization rates of 2.9% at six months and 4.0% at one year, and a low 0.5% thrombosis rate at one year. Results of the pooled analysis were featured in a tools and techniques session chaired by Dr. Wijns and Martin B. Leon, M.D., of Columbia University, New York. The session featured two successful live case transmissions using the Tryton stent, including a left main bifurcation, by Eulogio Garcia, M.D., of the Hospital Clinico San Carlos in Madrid, Spain.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 27, 2012